Ascelia Pharma AB (publ) (STO:ACE)
Sweden · Delayed Price · Currency is SEK 3.015
+0.015 (0.50%)
May 4, 2026, 5:29 PM CET
Ascelia Pharma AB Market Cap
Ascelia Pharma AB has a market cap or net worth of 402.61 million as of May 4, 2026. Its market cap has increased by 55.44% in one year.
Market Cap
402.61M
Enterprise Value
353.72M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
3.02
Market Cap Chart
Since March 13, 2019, Ascelia Pharma AB's market cap has decreased from 562.35M to 402.61M, a decrease of -28.41%. That is a compound annual growth rate of -4.57%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 30, 2026 | 400.61M | -1.78% |
| Dec 30, 2025 | 407.88M | 45.35% |
| Dec 30, 2024 | 280.63M | 146.68% |
| Dec 29, 2023 | 113.76M | -77.38% |
| Dec 30, 2022 | 503.00M | -49.95% |
| Dec 30, 2021 | 1.00B | -36.78% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Mar 13, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| FluoGuide | 668.69M |
| Oncopeptides AB | 515.45M |
| Corline Biomedical AB | 411.10M |
| Intervacc AB | 389.21M |
| Sprint Bioscience AB | 328.15M |
| Mendus AB | 314.72M |
| Bio-Works Technologies AB | 314.03M |
| Xbrane Biopharma AB | 226.66M |